Can a brief chat help young people with psychosis cut back on pot?
NCT ID NCT04624074
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This pilot study tested a counseling program called the Teen Marijuana Check Up, adapted for young adults (ages 13–35) who have early psychosis and use cannabis. The program uses motivational interviewing and personalized feedback over two sessions to help participants reduce or stop cannabis use. Researchers measured changes in cannabis use and psychosis symptoms in 17 participants enrolled in coordinated specialty care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- behavioral intervention (Teen Marijuana Check Up adapted for psychosis)
- What this could lead to
- If successful, this could provide a practical counseling approach to help young people with psychosis cut back on cannabis and stay engaged in care.
- What could go wrong
- This is a very small pilot study with only 17 participants, so results may not apply broadly. The intervention is behavioral and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
17 people
The number who actually took part.
- Started
-
Jan 2021
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
13 to 35 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 13-35 2. DSM-5 diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, delusional disorder, other specified schizophrenia spectrum and other psychotic disorder, and unspecified schizophrenia spectrum and other psychotic disorder 3. Duration of illness: ≤ 2 years 4. Enrolled at a Coordinated Specialty Care program 5. Report current use of cannabis 6. Ability and willingness to provide informed consent to participate Exclusion Criteria: 1\. Individuals who do not meet all inclusion criteria are excluded.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cannabis use disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Maryland School of Medicine
Baltimore, Maryland, 21021, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may reveal if You're taking your psychiatric medication
- Can a website help people cut back on cannabis?
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial